Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

We report a long‐term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long‐term outcome was evaluated in this subcohort of the patients. We examined the duration to reach Stage III, IV, and V, and the duration to develop wearing off and dyskinesia. Time to reach Stage III was slightly but significantly shorter in women, in that 23.8% of men and 35.3% of women reached Stage III by the end of the 5th year; 49.7% of men and 63.3% of women reached Stage III by the end of the 10th year, and 88.9% of men and 79.9% of women by the end of the 15th year (P < 0.001). Also, durations to develop wearing off and dyskinesia were shorter in women compared to men. These data suggest that the disease progression may be slightly faster for women. Young‐onset patients showed significantly longer duration to reach Stage III, IV, and V but shorter duration to develop wearing off and dyskinesia. Not many studies are available in the literature on the long‐term outcome of PD, and our data would be useful as a reference. © 2006 Movement Disorder Society

[1]  C. Tanner,et al.  Risk factors for progression in Parkinson's disease , 1988, Neurology.

[2]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[3]  R. Mindham,et al.  Mortality in Parkinson's disease and its association with dementia and depression , 2004, Acta neurologica Scandinavica.

[4]  A. Hofman,et al.  Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[5]  D. Perl,et al.  Two decades of increasing mortality from Parkinson's disease among the US elderly. , 1990, Archives of neurology.

[6]  M. Hely,et al.  The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years , 1999, Journal of neurology, neurosurgery, and psychiatry.

[7]  K P Offord,et al.  Epidemiology of parkinsonism: Incidence, classification, and mortality , 1984, Annals of neurology.

[8]  J. Olsson,et al.  Survival time, mortality, and cause of death in elderly patients with Parkinson's disease. A 9‐year follow‐up , 2003, Movement disorders : official journal of the Movement Disorder Society.

[9]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[10]  M. Hoehn.  Parkinson's disease: progression and mortality. , 1987, Advances in neurology.

[11]  P. Ragonese,et al.  Parkinson disease survival: a population-based study. , 2000, Archives of neurology.

[12]  R. Barker,et al.  Movement Disorders , 1994, Stereotactic and Functional Neurosurgery.

[13]  Klaus P. Ebmeier,et al.  Parkinson's disease in Aberdeen: survival after 3.5 years , 1990, Acta neurologica Scandinavica.

[14]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.

[15]  A. Hofman,et al.  Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[16]  C. Markham,et al.  Effect of age at onset on progression and mortality in Parkinson's disease , 1989, Neurology.

[17]  Hoehn Mm,et al.  Parkinson's disease: progression and mortality. , 1987 .

[18]  K. Nakashima,et al.  Prognosis of Parkinson's disease in Japan. Tottori University Parkinson's Disease Epidemiology (TUPDE) Study Group. , 1997, European neurology.

[19]  D. Morens,et al.  Epidemiologic observations on Parkinson's disease , 1996, Neurology.

[20]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[21]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[22]  K. Sewing,et al.  Effects of histamine on protein and glycoprotein production of isolated pig gastric mucosal cells. , 1990, Pharmacology.

[23]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[24]  L A Beckett,et al.  Prevalence of parkinsonian signs and associated mortality in a community population of older people. , 1996, The New England journal of medicine.

[25]  Geographical variations in mortality from Parkinson's disease in Japan, 1977–1985 , 1995, Acta neurologica Scandinavica.

[26]  K. Nakashima,et al.  Prognosis of Parkinson’s Disease in Japan , 1997 .

[27]  C. Markham,et al.  An examination of male‐female differences in progression and mortality of Parkinson's disease , 1990, Neurology.

[28]  Y. Agid,et al.  Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint , 1999, Movement disorders : official journal of the Movement Disorder Society.

[29]  Daniel J Schaid,et al.  Survival study of Parkinson disease in Olmsted County, Minnesota. , 2003, Archives of neurology.

[30]  J. Boldsen,et al.  Mortality in patients with Parkinson's disease , 1995, Acta neurologica Scandinavica.

[31]  A Schrag,et al.  Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. , 2000, Brain : a journal of neurology.

[32]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[33]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study , 1999 .

[34]  J. Jankovic,et al.  Functional decline in Parkinson disease. , 2001, Archives of neurology.

[35]  M. Schiess,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. , 2000, Neurology.

[36]  F. Mcdowell,et al.  Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. , 1975, Annals of internal medicine.

[37]  M. Musicco,et al.  Mortality associated with early and late levodopa therapy initiation in Parkinson's disease , 1990, Neurology.

[38]  M. Marmot,et al.  Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? , 1995, Journal of neurology, neurosurgery, and psychiatry.

[39]  M. Yen,et al.  Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan County, Taiwan , 2001 .

[40]  P. Kempster,et al.  Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[41]  C. Naylor,et al.  Parkinsonism in Ontario: Increased mortality compared with controls in a large cohort study , 2001 .

[42]  C. Joseph,et al.  Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.

[43]  J. Riggs.  Longitudinal Gompertzian analysis of Parkinson's disease mortality in the U.S., 1955–1986: The dramatic increase in overall mortality since 1980 is the natural consequence of deterministic mortality dynamics , 1990, Mechanisms of Ageing and Development.

[44]  M. Adena,et al.  Age at onset: the major determinant of outcome in Parkinson's disease , 1995, Acta neurologica Scandinavica.

[45]  B. Snow,et al.  Criteria for diagnosing Parkinson's disease , 1992, Annals of neurology.

[46]  P. Rochon,et al.  Predicting motor decline and disability in Parkinson disease: a systematic review. , 2002, Archives of neurology.

[47]  Y. Minami,et al.  Mortality and cancer incidence in patients with Parkinson's disease , 2000, Journal of Neurology.

[48]  M. Musicco,et al.  The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa , 1991, Neurology.

[49]  E. van der Velde,et al.  Clinical course of patients with idiopathic Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[50]  C. Markham,et al.  Evidence to support early levodopa therapy in Parkinson disease , 1981, Neurology.

[51]  G. Meco,et al.  Mortality in a population‐based cohort of patients treated with antiparkinsonian drugs , 1998, Acta neurologica Scandinavica.

[52]  Longitudinal Gompertzian analysis of parkinson's disease mortality in Japan, 1950–1993 , 1995, Mechanisms of Ageing and Development.

[53]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.